Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.


Icli F., Altundag K., Coskun U., Paydas S., Basaran G., Saip P., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.29, sa.15, 2011 (SCI-Expanded) identifier